Cuvrior (Trientine Tetrahydrochloride) Patent Expiration, LOE Window & CMS Spending

Cuvrior (Trientine Tetrahydrochloride) by Orphalan Sa: FDA Orange Book core substance LOE 2039-05-03, 0 AB generics, $3.3M 2024 CMS Part D & Medicaid spend, and $13,752 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorOrphalan Sa
FDA Application & PathwayN215760 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2039-05-03
Last Listed Patent or Exclusivity Date2039-05-03
Orange Book Patents (*PED Extensions)5 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$3.3M
2024 Medicare Part D Spend$1.6M
2024 Medicaid Spend$1.7M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($13,752 intro WAC)